Life Science Valley

Life Science Valley

The firm was established as a consortium of regional scientific and industrial stakeholders in the Göttingen life-science ecosystem. Its formation reflects a deliberate policy choice by the State of Lower Saxony and local institutions to retain high-value academic spinouts. The incubator acts as a central entry point for scientists and clinicians seeking to commercialize research in diagnostics, therapeutics, medical devices and digital health. The strategy centers on pre-seed and seed-stage company building. Life Science Valley provides a bundled offering: non-dilutive grants, flexible wet-lab and office infrastructure, and access to a vetted network of mentors and corporate partners. The program is stage-specific, guiding founders from initial concept validation through to a viable corporate entity capable of attracting follow-on venture funding. The geographic focus is the Göttingen region, with an explicit mandate to serve national and international founders willing to relocate into this research hub. Since 2022 the incubator has been funded as a state-level Hightech-Inkubator. In the most recent cycle, the Lower Saxony Ministry for Economic Affairs committed EUR 1.5 million to extend the program through 2029. The firm marked the close of its 2022–2024 funding period with a Demo Day in 2024, showcasing graduating companies to investors and corporate partners. Life Science Valley is currently recruiting for a Venture Manager and a Community Manager role to expand its operational capacity. Life Science Valley's structural differentiator is its deep integration with the University of Göttingen and affiliated Max Planck institutes. Unlike a conventional venture fund that deploys committed LP capital for equity, the incubator operates primarily via government grant facilities and in-kind infrastructure support. This hybrid model allows it to de-risk earliest-stage life-science ventures — where traditional venture capital remains scarce — without pressing for immediate equity dilution, before handing companies off to later-stage investors who value the technical validation this process provides.